BPC-157 vs TB-500: how the two peptides differ, why they are studied together, and how to handle a blend

BPC-157 and TB-500 are the two peptides most often mentioned in the same breath, and the most often confused. They have different origins, sizes, proposed mechanisms and evidence bases, and the only thing they share is a reputation built on rodent tissue models. This guide puts them side by side, explains why laboratories study them in combination, and covers the practical points of working with a co-lyophilized blend. For laboratory research use only.

Side by side

	BPC-157	TB-500 (thymosin β4)
What it is	Synthetic 15-residue fragment of a gastric-juice protein	Synthetic copy of thymosin β4, a 43-residue actin-binding peptide found in nearly all cells
Sequence length	15 amino acids	43 amino acids, N-acetylated
Molecular weight	≈ 1,419.5 g/mol	≈ 4,963 g/mol
CAS number	137525-51-0	77591-33-4
Origin	University of Zagreb group, early 1990s	Isolated 1981 (Goldstein lab); endogenous in humans
Proposed mechanism (literature)	Nitric-oxide system, angiogenesis signalling, growth-factor expression	G-actin sequestration; cell migration; Ac-SDKP fragment
Main research models	Rat GI, tendon, ligament, muscle injury	Cell migration assays; rodent dermal, corneal and cardiac models
Human data	None published	Trials of pharmaceutical Tβ4 formulations (topical, ophthalmic); none for the research reagent
Oxidation-sensitive residues	None (no Cys or Met)	One methionine (Met-6); no Cys
Solubility	Water, bacteriostatic water	Water, bacteriostatic water, PBS

Where they come from

BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV) that the Sikirić group in Zagreb derived from a protein they isolated from human gastric juice. It does not exist on its own in the body; it is a laboratory-defined fragment. Nearly all of its literature is from that one group. Our BPC-157 research overview covers it in detail.

TB-500 is the catalogue name for synthetic thymosin β4, a naturally occurring 43-residue peptide that is one of the most abundant small proteins in mammalian cells and the main intracellular buffer of unpolymerised actin. Its literature is broader and older, spans many laboratories, and includes sponsored clinical trials of pharmaceutical formulations. A complication specific to TB-500 is that some suppliers use the name for a seven-residue fragment (residues 17–23) rather than the full peptide; the certificate’s observed mass tells you which you have. Our TB-500 research overview explains the naming problem.

How the proposed mechanisms differ

The two peptides are not variations on a theme. The BPC-157 literature proposes effects through the nitric-oxide system, vessel recruitment and growth-factor and receptor expression (VEGFR2, for example), based on rat injury models and endothelial-cell culture. The thymosin β4 literature is built on a defined biochemical function, 1:1 binding of G-actin, with downstream effects on cytoskeletal remodelling and cell migration, plus a separate activity attributed to its N-terminal tetrapeptide Ac-SDKP, which is released by cleavage. If the two act on the same tissue models, the literature suggests they do so by different routes, which is the rationale usually given for studying them together.

Why they are studied in combination

Both peptides appear in the same families of experiments: tendon and ligament models, dermal wound models, fibroblast and endothelial migration assays. Laboratories interested in whether two mechanistically distinct agents are additive in such models have an obvious reason to run them together, and a co-lyophilized vial, with a defined mass of each, removes the weighing and dispensing error of preparing two separate stocks and mixing them. That is the practical case for a blend. It is not a claim that the combination has been shown to be superior to either peptide alone; controlled comparisons of the combination against each component are scarce, and none exist in humans.

Working with a BPC-157 / TB-500 blend

Quantum Peptides supplies the two peptides co-lyophilized as the BPC-157 / TB-500 blend, 10 mg + 10 mg, and with GHK-Cu added in the three-peptide Glow peptide blend. Each lot certificate reports every component separately: identity by mass spectrometry and purity by HPLC for each peptide. Practical points:

• Concentration is per component. In the 10 mg + 10 mg vial reconstituted with 2 mL, each peptide is at 5 mg/mL. Enter each mass separately in the peptide calculator; the molar concentrations differ because the molecular weights differ by a factor of 3.5.
• Fixed ratio. A blend locks the mass ratio. If an experiment needs to vary the ratio, or needs one peptide alone as a control arm, buy the single compounds. Our guide to peptide blends in research covers when a blend is and is not the right format.
• Compatibility. Both peptides are water-soluble and tolerate the same diluents and storage conditions; BPC-157 has no oxidation-prone residue and thymosin β4 has a single methionine, so a blend of the two has no special handling requirement beyond that of the more fragile component (the 43-residue chain, which can oxidise at Met-6 and degrades in solution over weeks).
• Reconstitution and storage. As for any lyophilized peptide: diluent down the vial wall, swirl, do not shake; store the powder at −20 °C and solutions at 2–8 °C in the dark. See the reconstitution guide and bacteriostatic vs sterile water.

Frequently asked questions

Is TB-500 the same as BPC-157?

No. BPC-157 is a 15-residue synthetic fragment of a gastric protein; TB-500 is synthetic thymosin β4, a 43-residue natural actin-binding peptide. They differ in origin, size, mechanism and evidence base.

Which has more research behind it?

Thymosin β4 has the broader and more independent literature, including a defined biochemical mechanism and clinical trials of pharmaceutical formulations. The BPC-157 literature is larger in paper count but comes almost entirely from one group and is all preclinical.

Why are BPC-157 and TB-500 sold as a blend?

Because they are commonly studied together in the same tissue and migration models, and a co-lyophilized vial with a defined mass of each avoids the dispensing error of mixing two stocks.

How do I calculate the concentration of a blend?

Per component: divide each peptide’s mass by the diluent volume. 10 mg + 10 mg in 2 mL is 5 mg/mL of each. The calculator handles one component at a time.

Can I buy these peptides for human use?

No. Quantum Peptides products are supplied for in-vitro and preclinical laboratory research only, not for human or veterinary use.

References

1. Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021.
2. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.
3. Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991.

Quantum Peptides supplies lyophilised research peptides for in-vitro and preclinical laboratory research only. Products are not for human or veterinary use. This guide summarises published literature and is not guidance on administration of any kind.